Marinus Pharma CS (MRNS)

$1.35 0.02 (1.50%)

13:47 EDT MRNS Stock Quote Delayed 30 Minutes

MRNS Stock Earnings: Marinus Pharma Misses EPS, Misses Revenue for Q1 2024

By InvestorPlace Earnings May 8, 2024

MRNS stock results show that Marinus Pharma missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.

Biotech on a Budget: 7 Stocks Under $10 With Huge Potential

Why Is Marinus Pharmaceuticals (MRNS) Stock Down 79% Today?

MRNS Stock Earnings: Marinus Pharma Misses EPS, Misses Revenue for Q4 2023

More Articles

Volume:

Previous Close -

Market Cap 74.16M

PE Ratio -0.51

EPS -2.64

Volume (Avg. Vol.) 786,257

Day's Range $1.27 - $1.36

52-Week Range $1.11 - $11.26

Dividend & Yield N/A (N/A)

MRNS Stock Predictions, Articles, and Marinus Pharma CS News

From InvestorPlace
From the Web

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

By William White, InvestorPlace Writer Nov 8, 2022

We're starting off the day with a look at the biggest pre-market stock movers traders need to know about on Tuesday morning!

7 Sizzling Stocks That Are Oblivious to the Manic Market

By Josh Enomoto, InvestorPlace Contributor Oct 20, 2022

While some stocks to buy have performed surprisingly well recently, they remain relatively obscure, providing a contrarian opportunity.

7 Disruptive Biotech Stocks to Buy for 2025

By Harriet Lefton, Writer, TipRanks Apr 27, 2020

RBC Capital has peered into its crystal ball to reveal some of the market's most exciting biotech stocks. Here are seven that stand out.

10 Killer Stocks to Buy That No One Knows About

By Harriet Lefton, Writer, TipRanks Oct 12, 2018

The best way to earn big gains is to find stocks to buy that are off the beaten path. These 10 stars are definitely worth your time.

Marinus Pharmaceuticals Stock (NASDAQ:MRNS): This Drugmaker Boasts a Rare Treatment

From TipRanks Jan 30, 2024

Among the range of central nervous system (CNS) disorders afflicting patients in the U.S. each year, status epilepticus (SE) — a condition marked by continuous seiz...

BZUN, CMPS and QSI are among after hour movers (NASDAQ:MRNS)

From Seeking Alpha Sep 20, 2023

Gainers: Marinus Pharmaceuticals (MRNS) +8%. Complete Solaria (CSLR) +5%

Marinus stock jumps 11% on financial, pipeline updates (NASDAQ:MRNS)

From Seeking Alpha Sep 19, 2023

Marinus Pharmaceuticals (MRNS) shares jumped 11% Tuesday after the company issued updates on its financial position, pipeline and guidance at an investor event. Read more here.

Marinus gets EU approval for anti-seizure treatment Ztalmy (NASDAQ:MRNS)

From Seeking Alpha Jul 31, 2023

Marinus Pharmaceuticals (MRNS) and partner Orion Oyj (ORINY) said that the European Commission has granted market approval for Marinus anti-seizure drug Ztalmy. Read more here.

Marinus gets new method of use patent approval for ganaxolone (NASDAQ:MRNS)

From Seeking Alpha Jun 21, 2023

Marinus Pharmaceuticals (MRNS) said Wednesday that the United States Patent and Trademark Office has granted a new method of use patent for intravenous ganaxolone in the treatment of...

Analysts Are Bullish on These Healthcare Stocks: Marinus (MRNS), KalVista Pharmaceuticals (KALV)

From TipRanks Dec 9, 2022

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Marinus (MRNS – Research Report), KalVista Pharmaceu...

ADVERTISEMENT